
    
      Subjects with chronic hives that do not respond to antihistamine treatment and have hives of
      unknown cause will be eligible. Subjects who meet the inclusion/exclusion criteria after the
      run-in phase will receive 3 doses of study medication. The study also involved blood draws
      and a punch biopsy of a hive
    
  